Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference

Rhea-AI Summary

Moleculin Biotech (Nasdaq: MBRX) announced that CEO and Chairman Walter Klemp participated in the Virtual Investor “Why Now” on-demand conference, where he highlighted the Company’s clinical progress and long-term opportunity.

The presentation discussed encouraging interim results from the pivotal Phase 2/3 MIRACLE trial (MB-108) of Annamycin (naxtarubicin) for relapsed or refractory acute myeloid leukemia (AML), its differentiated clinical profile, continued enrollment, expanding commercial opportunity, and an upcoming 90-patient interim analysis viewed by the Company as a key potential value catalyst toward registration. The webcast is now available for on-demand viewing. Moleculin also outlined its broader pipeline, including Annamycin for soft tissue sarcoma lung metastases, the immune/transcription modulator WP1066 for various cancers, and antimetabolites such as WP1122 for pathogenic viruses and certain cancers.

Market Context

Recent filings recorded 2,399,997 shares bought and 0 shares sold by insiders, adding ownership cont...

Analysis

Recent filings recorded 2,399,997 shares bought and 0 shares sold by insiders, adding ownership context to this conference update. The platform record also showed an active S-3 resale registration; future trial and financing needs remained relevant.

Key Figures

MIRACLE trial phase: Phase 2/3 Interim analysis size: 90 patients Prior study phase: Phase 1B/2 +1 more

4 metrics

MIRACLE trial phase Phase 2/3 Pivotal trial evaluating Annamycin with cytarabine

Interim analysis size 90 patients Upcoming MIRACLE interim analysis

Prior study phase Phase 1B/2 Successful MB-106 study

Company development stage Phase 3 Clinical-stage pharmaceutical company

Historical Context

5 past events · Latest: Aug 14 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 14	2Q26 earnings report	Positive	+6.0%	Reported quarterly results alongside continued MIRACLE trial progress and updated funding outlook.
Jul 31	Public offering	Negative	-60.8%	Priced a $9.3 million offering with shares and warrants for clinical development funding.
Jul 31	Clinical trial update	Positive	-60.8%	Reported blinded MIRACLE remission data and enrollment progress toward 90 Part A subjects.
Jul 06	Investor presentation	Positive	-9.1%	CEO discussed preliminary unblinded efficacy results and Annamycin’s commercial opportunity.
Jun 30	Clinical trial data	Positive	-21.9%	Reported interim remission rates favoring Annamycin over the control arm.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history showed divergence on three positive clinical or news events, while the earnings and offering events aligned with their price reactions.

Key Terms

anthracycline, cardiotoxicity, adaptive design, double-blind, +2 more

6 terms

anthracycline medical

"a highly efficacious and well tolerated anthracycline designed"

An anthracycline is a type of powerful medicine used to treat cancer, working by killing or stopping the growth of cancer cells. Because these drugs can have significant side effects and influence healthcare costs, they are closely watched by investors, especially in the pharmaceutical and healthcare sectors. Their development and use can impact the financial performance of companies involved in cancer treatment.

cardiotoxicity medical

"to lack the cardiotoxicity common with currently prescribed"

Cardiotoxicity is damage to the heart caused by a drug, chemical or medical treatment that can weaken heart function, disrupt heartbeat or cause inflammation. It matters to investors because evidence of cardiotoxicity can halt or delay product approvals, trigger costly additional testing, recalls or legal risk, and reduce future revenue potential—similar to how rust in an engine can undermine a machine’s reliability and resale value.

adaptive design technical

"a pivotal, adaptive design, multi-center, randomized"

Adaptive design is a way to run clinical trials that lets researchers change aspects of the study—such as dose, sample size, or which patient groups are studied—based on data gathered while the trial is ongoing, without starting over. For investors, it matters because this flexibility can shorten development time, reduce costs, and increase the chance of finding a successful outcome, similar to steering a ship toward calmer waters as conditions change.

double-blind technical

"randomized, double-blind, placebo-controlled Phase 2/3"

A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.

placebo-controlled technical

"double-blind, placebo-controlled Phase 2/3 trial evaluating"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

p-stat3 medical

"capable of inhibiting p-STAT3 and other oncogenic"

p-STAT3 is the activated form of a cellular signaling protein called STAT3, produced when the protein is chemically modified (phosphorylated) and can turn genes on or off. For investors, p-STAT3 is important because its presence or reduction in lab tests or clinical samples can indicate whether a drug is hitting its intended target, predict how aggressive a disease like cancer may be, and help gauge a therapy’s development and commercial potential—think of it as a molecular ‘on’ switch that shows whether a treatment is working.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

- Video webcast now available here

HOUSTON, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it participated in the Virtual Investor “Why Now” on-demand conference.

During the presentation, Walter Klemp, Chairman and Chief Executive Officer of Moleculin, highlighted the Company's clinical progress and long-term opportunity, discussing encouraging interim results from the pivotal Phase 2/3 MIRACLE trial evaluating Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (AML). The presentation also emphasized Annamycin's differentiated clinical profile, continued enrollment progress, expanding commercial opportunity, and the upcoming 90-patient interim analysis as a key value-driving catalyst supporting the Company's path toward potential registration.

The video webcast is now accessible for on-demand viewing here.

JTC Team and Virtual Investor Co. are paid consultants to Moleculin Biotech, Inc. JTC Team and Virtual Investor Co. are investor relations and corporate communications firms. Any content included in this release shall not be construed as an offer to purchase securities of Moleculin Biotech, Inc. Interested parties are responsible for conducting their own due diligence and are encouraged to review the Company's website and the SEC website for the latest information and filings on the Company.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin (also known as naxtarubicin), is a highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

The Company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design, multi-center, randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC (the combination of Annamycin and cytarabine, also referred to as “Ara-C”) for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.

For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the potential efficacy and safety of Annamycin and AnnAraC in R/R AML and the expectation that interim efficacy trends observed in a limited patient population will be confirmed in the full study population (the interim results presented are based on a small sample size (n=45), have not achieved statistical significance, and may not be predictive of results from the completed trial). Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company’s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company relies on the reports of its expert with regard to the absence of cardiotoxicity. The dataset referenced in this press release is subject to the review of the data from future subjects in its current and future clinical trials and long-term follow-up with subjects in its current trials. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com

FAQ

What did Moleculin Biotech (NASDAQ: MBRX) present at the Virtual Investor "Why Now" conference on August 27, 2026?

Moleculin Biotech presented clinical progress and long-term opportunity, focusing on Annamycin and the MIRACLE trial. According to Moleculin, the talk covered encouraging interim results in relapsed or refractory AML, Annamycin’s differentiated profile, enrollment progress, and the upcoming 90-patient interim analysis as a key potential catalyst.

How can investors watch Moleculin Biotech’s August 2026 Virtual Investor "Why Now" conference webcast for MBRX?

Investors can access Moleculin Biotech’s Virtual Investor "Why Now" presentation via an on-demand video webcast. According to Moleculin, the webcast is now available online for replay, allowing interested parties to review the Company’s clinical updates, MIRACLE trial discussion, and pipeline overview at their convenience.

What is the MIRACLE Phase 2/3 trial of Annamycin that Moleculin Biotech (MBRX) discussed at the conference?

The MIRACLE trial (MB-108) is a pivotal, adaptive, randomized, double-blind, placebo-controlled Phase 2/3 study. According to Moleculin, it evaluates Annamycin in combination with cytarabine (AnnAraC) for relapsed or refractory AML, following a successful Phase 1B/2 study with FDA input guiding the development pathway.

What upcoming catalyst did Moleculin Biotech highlight for Annamycin and the MIRACLE AML trial (MBRX)?

Moleculin highlighted an upcoming 90-patient interim analysis in the MIRACLE trial as a key potential value-driving catalyst. According to Moleculin, this analysis is viewed as supporting the Company’s path toward potential registration of Annamycin for relapsed or refractory acute myeloid leukemia, subject to regulatory review.

What is Annamycin (naxtarubicin), Moleculin Biotech’s lead program, and what indications is MBRX targeting?

Annamycin is a highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance and cardiotoxicity. According to Moleculin, it is in development for relapsed or refractory AML and soft tissue sarcoma lung metastases within the Company’s Phase 3 clinical-stage oncology pipeline.

Which additional pipeline programs besides Annamycin did Moleculin Biotech (NASDAQ: MBRX) reference around the August 2026 conference?

Moleculin referenced WP1066, an immune/transcription modulator targeting brain tumors, pancreatic and other cancers, and antimetabolites including WP1122. According to Moleculin, WP1122 is being developed for potential treatment of pathogenic viruses and certain cancers, complementing the Annamycin franchise in hard-to-treat indications.